This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by almost half compared to people taking a placebo.

03/03/15 - 11:51 AM EST

Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'

  • Tickers in this article:
  • MNKD

Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.

03/03/15 - 11:28 AM EST

MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch

MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch

  • Tickers in this article:
  • MNKD
  • SNY

The slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for all diabetes products compels Goldman Sachs to slap a 'sell' rating on MannKind.

03/03/15 - 08:16 AM EST

Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'

Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'

  • Tickers in this article:
  • MNKD

Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.

03/03/15 - 11:28 AM EST

March Mergers Take Off With Multi-Billion Tech, Healthcare Deals

March Mergers Take Off With Multi-Billion Tech, Healthcare Deals

March madness has nothing on Wall Street as the first Monday in the month kicks off with several multi-billion dollar deals.

03/02/15 - 01:08 PM EST

Boston Scientific Buys Endo's Urology Device Business in $1.6 Billion Deal

Boston Scientific Buys Endo's Urology Device Business in $1.6 Billion Deal

  • Tickers in this article:
  • BSX
  • ENDP

Sale of its men’s urology portfolio continues Endo’s move into pharmaceuticals.

03/02/15 - 11:57 AM EST

Opko Health (OPK) Stock Falls Today Following Earnings Miss

Opko Health (OPK) Stock Falls Today Following Earnings Miss

  • Tickers in this article:
  • OPK

Opko Health (OPK) shares decline on their fourth quarter earnings miss.

03/02/15 - 11:08 AM EST

Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data

Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data

  • Tickers in this article:
  • ATHX

Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.

03/02/15 - 09:38 AM EST

Amgen Multiple Myeloma Drug Kyprolis Tops Rival in Study

Amgen Multiple Myeloma Drug Kyprolis Tops Rival in Study

  • Tickers in this article:
  • AMGN

Amgen believes proving Kyprolis' superiority over Velcade in the second-line multiple myeloma treatment setting further justifies the $10.4 billion paid to Onyx Pharmaceuticals.

03/01/15 - 10:25 PM EST

A Battle Rages Over Whether an Old Drug Can Be New Again

A Battle Rages Over Whether an Old Drug Can Be New Again

  • Tickers in this article:
  • UTHR
  • NVS

Takeover candidate United Therapeutics fights Sandoz over patents for treating a rare disorder.

02/27/15 - 01:58 PM EST

Horizon Pharma (HZNP) Stock Spikes Today on Raised Guidance Despite Quarterly Earnings Loss

Horizon Pharma (HZNP) Stock Spikes Today on Raised Guidance Despite Quarterly Earnings Loss

  • Tickers in this article:
  • HZNP

Horizon Pharma (HZNP) shares are up almost double digits following the company's earnings beat and revised fiscal 2015 guidance.

02/27/15 - 10:31 AM EST

FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market

FireEye, 3 More Are Hot Momentum Stocks Despite Overheated Market

BroadSoft, TG Therapeutics and Ziopharm Oncology also have room for further gains, according to a technical analysis of their recent stock activity.

02/27/15 - 06:30 AM EST

GlaxoSmithKlein's Diet Pill Alli Back in Stores After Recall

GlaxoSmithKlein's Diet Pill Alli Back in Stores After Recall

  • Tickers in this article:
  • GSK

GlaxoSmithKline's diet pill, alli, is now back in most U.S. stores.

02/25/15 - 09:48 AM EST

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.

02/25/15 - 11:47 AM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs